Inclusion Criteria:  Age of at least 18 years at study entry; Histologically confirmed adenocarcinoma of the prostate; 68Ga-PSMA-PET in patients with prostate cancer 68Ga-PSMA-PET exam performed between October 2015 and January 2021;  68Ga-PSMA-PET performed in one of the following situations:  localized disease at diagnosis in patients with no detection of extra-prostatic disease in traditional imaging such as CT scan, MRI and bone scan; biochemical recurrence (according to PCWG3 or defined by the investigator) in patients with no detection of prostatic or extra-prostatic disease in traditional imaging such as CT scan, MRI and bone scan; Traditional imaging (pelvic and abdominal CT or MRI and bone scan) with negative results (no extra-prostatic disease, for localized and biochemical recurrence disease; no prostatic for biochemical recurrence disease) performed within 8 weeks before 68Ga-PSMA-PET; Site and investigator ability to collect adequate patient characteristics, treatment and outcome data from medical records.  Exclusion Criteria:  Patients with no disease characteristics accessible in medical records; Cancer diagnosis other than prostate cancer in the last 5 years; Disease detected by traditional imaging techniques (bone scan, CT and/or MRI), meaning extra-prostatic disease, for localized and biochemical recurrence disease; or prostatic disease for biochemical recurrence disease.